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ABSTRACT
The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) evolved to stimulate the ex-
pression of intronless viral messages. To determine whether this ability to enhance expression could be use-
ful in nonviral and heterologous viral gene delivery systems, we analyzed the ability of the WPRE to elevate
the expression of a cDNA encoding the green fluorescent protein (GFP) in these contexts. We find that the
WPRE can stimulate the expression of GFP when the gene is delivered by transfection or transduction with
recombinant adeno-associated virus (AAV). Enhancement occurred both during transient expression and when
the gene is stably incorporated into the genome of target cells. This enhancement required that the WPRE be
located in cis within the GFP message, and was observed in both transformed cell lines and primary human
fibroblasts. These results demonstrate that the WPRE will be an effective tool for increasing the long-term
expression of transgenes in gene therapy.
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OVERVIEW SUMMARY
The optimization of transgene  expression  at the posttran-
scriptional  level  will enhance the capacity  of vector  deliv-
ery systems to produce therapeutic results in target tissues.
In this study, the woodchuck hepatitis virus posttranscrip-
tional regulatory element (WPRE) is shown to enhance the
expression of an eGFP reporter gene in both transient and
stable contexts, when delivered either by transfection or by
transduction with recombinant AAV. This enhancement of
transgene  expression  is observed  both in cell  lines  and in
primary  cells.  Inclusion  of  the WPRE in transgenic  mes-
sages will better the prospects for therapeutic levels of trans-
gene expression using currently existing gene delivery tech-
nologies.
INTRODUCTION
T
HE EFFECTIVE DELIVERY of transgenes to target cells for ther-
apeutic  purposes  will require  strategies  that optimize this
process  at each  step.  Previous  efforts  at enhancing  transgene
expression  have largely  been directed  at improving  efficiency
of  delivery  and  increasing  levels  of  transcription.  Gene  ex-
pression can be modulated at many levels, including transcrip-
tion, posttranscriptional  modification of RNA such as 59 and 39
end processing, RNA export and stability, and translation. Un-
derstanding  of the mechanisms by which viruses posttranscrip-
tionally  modulate  expression  of their genes should enable  the
exploitation of these mechanisms for the purpose of improving
expression in gene therapy. Attempts at posttranscriptional  en-
hancement  have  primarily  been  limited to  the  addition  of  in-
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Wang et al., 1996).  In  these  reports,  the inclusion  of  introns
was shown  to  stimulate  gene  expression.  Although  the  exact
mechanism of this stimulation is not known, intronic sequences,
or  the  process  of  splicing  itself,  may  promote  39 processing
and/or facilitate cytoplasmic localization (Ryu and Mertz, 1989;
Nesic et al., 1993; Antoniou et al., 1998). Indeed, certain genes,
such as b -globin, are entirely dependent on the presence of in-
trons for expression  (Buchman and Berg, 1988).
It has previously been shown that the posttranscriptiona l reg-
ulatory  element  of hepatitis  B virus  (HPRE) can functionally
replace an intron in stimulating b -globin expression (Huang and
Yen,  1995).  Our  studies  of  the  woodchuck  hepatitis  virus
demonstrated that it contains a posttranscriptiona l regulatory el-
ement  (WPRE)  that  is  partially  homologous  to  the  HPRE
(Donello  et al., 1998).  Both PREs function  in an orientation-
dependent  manner,  suggesting  that  they  are  RNA  elements.
Consistent with this interpretation, the PREs contain conserved
RNA stem–loop structures that are required for maximal func-
tion (Smith et al., 1998). We find that the WPRE functions more
efficiently  than  the HPRE, owing to the presence  of an addi-
tional cis-acting  sequence  in the WPRE termed g (Donello et
al., 1998). The specific mechanism of this enhancement, while
not well understood,  is known to be posttranscriptional  in na-
ture and may involve the facilitation of RNA processing and/or
export (Harris et al., 1999; Huang et al., 1999).
Due to the high efficiency of the WPRE, we assayed the ef-
fectiveness  of  the  WPRE as  a means  of  enhancing  gene  ex-
pression  in  the  context  of  human  immunodeficiency  virus
(HIV)- and murine leukemia virus (MuLV)-based vectors. Our
studies  reveal that the posttranscriptiona l effect of the WPRE
can  significantly  stimulate  the  expression  of  luciferase  and
green  fluorescent  protein  (GFP)  in  a  promoter-independent
fashion  in both the retroviral  and lentiviral  systems (Zufferey
et al., 1999). The ability of the WPRE to elevate transgene ex-
pression posttranscriptiona lly in the retroviral context is an in-
dication that it may be useful in enhancing gene expression  in
the context  of other  potential  gene therapy  vectors.  However,
it is unclear that the results obtained in the retroviral vector sys-
tem can be extrapolated  to other  gene  delivery  systems.  Fea-
tures  that distinguish  retroviruses  generally,  such  as the pres-
ence of an RNA intermediate in the life cycle and the structure
of the provirus,  allow the possibility  that the WPRE may en-
hance  gene  expression  in this context  by ameliorating  the ef-
fects of inherent limitations of such a system. In this study, we
wished to determine whether the WPRE could be used as a tool
for the improvement  of transgene  expression  more generally.
Adeno-associated  virus  (AAV)  is  attractive  as  a  gene  thera-
peutic delivery  system (Carter, 1992; Kotin,  1994;  Flotte and
Carter,  1995)  and therefore  we chose  to test the effect  of the
WPRE in the context  of a recombinant  AAV (rAAV) vector.
This human parvovirus can transduce a wide range of host cells,
including nondividing  cells, and can yield stable integrants, al-
lowing long-term expression of transgenes (Cheung et al., 1980;
Laughlin et al., 1986; McLaughlin et al., 1988; Samulski et al.,
1989;  Flotte et al., 1993;  Xiao et al., 1996,  1997; Murphy  et
al., 1997;  Snyder  et  al., 1997.)  We find  that  the  WPRE can
stimulate gene expression in the context of transient and stable
transfection of 293 cells and rAAV transduction of transformed
cells and primary cells. Out results indicate that the strategy of
enhancing  gene  expression  posttranscriptional ly  with  the
WPRE is broadly  applicable,  and that multiple  gene  delivery
systems will benefit from its inclusion.
MATERIALS AND METHODS
Construction of eGFP plasmids
Plasmids used in transfection  and transduction  experiments
were based on the eGFP-C1 vector (Clontech, Palo Alto, CA).
Since the vector was originally intended for the construction of
enhanced  GFP  (eGFP)  fusion  proteins,  a  triple-frame  stop
codon  was inserted  after  the GFP reading  frame to allow the
use of the multiple cloning site for the addition of untranslated
elements. The triple stop was inserted as a pair of annealed syn-
thetic oligonucleotides of sequences gatcttagctaactg (sense) and
aatcagttagctaa  (antisense)  with BglII and EcoRI ends into the
eGFP-C1  vector  to  produce  the  plasmid  eGFP.stop.  Bases
900–1750  of the WPRE were amplified  by polymerase  chain
reaction  (PCR) from  the  viral  DNA template  of  WHV8  (ac-
cession  number  J04514),  to yield a product  with ClaI restric-
tion sites at each end. This fragment was cut with ClaI and in-
serted into the eGFP.stop vector at the AccI site, to produce the
plasmid eGFP.stop.WPRE.
To  adapt  the  constructs  for  use  in  AAV,  the  plasmid
eGFP.stop  was  cut  with  SspI  to  remove  the  f1  ori  and  amp 
promoter  and  religated,  reducing  the  size  of  the  recombinant
AAV  genome  eventually  generated  and  producing  plasmid
eGFP.stop.D Ssp. To allow transfer of the expression  cassettes
to the AAV shuttle vector psub201 (Samulski et al., 1987), syn-
thetic linkers  consisting  of annealed  oligonucleotides  contain-
ing XbaI restriction sites were inserted at the unique BspHI and
AseI sites in eGFP.stop.D Ssp, yielding eGFP.stop9 . The WPRE-
bearing derivative was constructed as before by insertion of the
ClaI-digested  PCR  product  at  the  AccI  site.  The  expression 
cassettes  with  and  without  WPRE were  then  transferred  into 
the  XbaI  site  of  the  AAV  shuttle  vector  psub201,  resulting 
in  pAAV.eGFP.W  and  psub201.eGFP.stop.  To  generate
pAAV.eGFP.W(as), bases 900–1750 of WHV8 were amplified
by  PCR to  yield  a product  with AseI restriction  sites  at each
end. The PCR product was cut with AseI and inserted in the an-
tisense orientation into the AseI site of the psub201.eGFP.stop
vector.  All final plasmid products  were grown in Escherichia
coli HB101  and  isolated  by  cesium  chloride  density  gradient
centrifugation.
Tissue culture and transfections
293 and HSF8 cells were grown at 37°C (5% CO2) in Dul-
becco’s modified Eagle’s medium supplemented with 10% fe-
tal calf serum (FCS). 293 cells  were transfected  at 30% con-
fluency  by  the  calcium  phosphate  method.  The  medium  was
changed after 18 hr. Cells transfected transiently were harvested
after  48  hr.  When  stable  selection  was  required,  geneticin
(G418,  200 m g/ml; GIBCO, Grand Island,  NY) was added to
the medium. Pools of stably transfected cells were analyzed af-
ter 4 weeks of selection  unless  otherwise  indicated.  For tran-
sient  transfections,  molar equivalents  of eGFP.stop (0.85  m g)
or  eGFP.stop.WPRE  (1  m g)  were  employed.  To  ascertain
whether any difference  in expression  was due to a difference
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19  m g  of  pCMXCD4,  a  cytomegalovirus  (CMV)  promoter-
driven  CD4  expression  vector.  Additional  pUC118  was 
included  to  equalize  the  total  amount  of  DNA  present  in 
each case. Mock and control transfections using pCMXCD4 or
eGFP.stop.WPRE  and  pUC118  were  equalized  for  total
amounts of DNA, and were used to set the quadrant gates dur-
ing flow cytometry.
Preparation of AAV stocks and transductions
Purified  viral  stocks  were  generated  by  cotransfecting  the
plasmids pAAV.eGFP.W(as) and pAAV.eGFP.W into 293 cells
with a Rep–Cap expression plasmid. Helper activities were sup-
plied using a plasmid cotransfection-bas ed system as described
(Xiao  et al., 1998).  Sixty  hours  after  transfection,  cells  were
lysed and the lysates fractionated  twice by density  centrifuga-
tion in cesium chloride (Fisher et al., 1996). Purified viral stocks
were titered by dot-blot hybridization  to a nitrocellulose  mem-
brane and comparison with known amounts of the starting plas-
mids; visualization  was achieved by hybridization  with a 32P-
labeled  GFP  probe.  Intensities  were  quantitated  with  a
PhosphorImager  (Molecular  Dynamics, Sunnyvale,  CA). The
degree of wild-type AAV was determined by infectious center
assays and in all preparations  was less than 0.1%. Cells were
transduced  in  Dulbecco’s  modified  Eagle’s  medium  supple-
mented with 2% fetal calf serum. 293 cells were transduced at
30% confluency,  HSF8 cells at 10%. Viral stocks were added
to the plates  and the cells  were incubated  at 37°C (5% CO2)
for 4 hr with occasional agitation, after which the medium was
supplemented  with additional  FCS to bring the serum content
to  10%.  Cells  were  harvested  for  fluorescence-activ ated  cell
sorting (FACS) analysis  after 48 hr or after 4 weeks selection
in G418 (200 m g/ml).
Flow cytometry
293 or HSF8 cells were harvested and resuspended  in phos-
phate-buffered  saline (PBS) at approximately  106 cells/ml. In
all cases, except the analysis of transiently transfected 293 cells,
in  which  an  R-phycoerythrin-conjugated  antibody  was  em-
ployed, propidium iodide was added to allow the exclusionary
gating of dead cells. Where cells were stained for surface CD4,
R-phycoerythrin-conjugated anti-CD4 antibody MT310 (Dako,
Carpinteria,  CA) was added to 106 cells at a 1:100 dilution in
1 ml of PBS–2% FCS. After incubation for 30 min at 4°C, the
cells were washed twice with 15 ml of cold PBS. All cells were
analyzed for eGFP expression on a Becton Dickinson (San Jose,
CA) FACScan. Within each experiment  the samples were an-
alyzed  on  the  same  day.  Results  are  reported  as  geometric
means.  The geometric  mean  yielded  values  for  fold  increase
that most closely  matched those obtained  by Western blotting
when both assays were performed.
RNA isolation  and analysis
Confluent cells from two 10-cm plates were harvested by re-
suspension  in  PBS and brief  centrifugation.  Isolation  of total
RNA was accomplished by resuspending the cell pellet in 1 ml
of  RNA STAT-50 LS (Tel-Test,  Friendswood,  TX). Nuclear
and cytoplasmic RNA samples were prepared as previously de-
scribed (Zufferey et al., 1999), except that the cytoplasmic ly-
sis buffer consisted  of 10 mM Tris (pH 8.0),  1.5 mM MgCl2,
140 mM NaCl, 20% glycerol, and 0.5% Nonidet P-40 (NP-40).
RNA was fractionated  on a 6% formaldehyde agarose gel and
transferred  to  Duralon  UV membranes  (Stratagene,  La  Jolla,
CA). Blots were hybridized  in Quikhyb (Stratagene) with ran-
dom  primed,  [32P]  dCTP-labeled  probes  generated  with  the
Prime-It II kit (Stratagene). The probe for eGFP was generated
by digestion of eGFP-C1 with NdeI and PstI; the probe for the
neomycin  resistance  gene  was  generated  by  digestion  with
AvrII. Fragments of 1131 and 1015 bp, respectively,  were pu-
rified from agarose  gels. Signals were visualized  by autoradi-
ography  and  quantitated  using  a  Molecular  Dynamics  Phos-
phorImager. Message size was assessed by mobility relative to
18S and 20S ribosomal RNA.
DNA isolation and analysis
Two 10-cm plates of confluent 293 or HSF8 cells were har-
vested. Genomic DNA was prepared using the QiaAmp blood
kit (Qiagen, Chatsworth, CA) according to the manufacturer in-
structions.  Genomic DNA (10 m g) was digested with PstI and
NdeI for G418-selected  lines transfected  with eGFP-C1 deriv-
atives. Digested DNA was fractionated  on 0.8% agarose–0.53
TBE  gels.  After  denaturation  and  neutralization,  DNA  was
transferred  to  Duralon  UV  membranes  (Stratagene)  and  hy-
bridized  with  32P-labeled  probes.  Signals  were  visualized  by
autoradiography  and  quantitated  with  a Molecular  Dynamics
PhosphorImager.  Fragment  size  was  assessed  by  comparison
with a l HindIII/EcoRI digestion  ladder.
Western analysis
293  cells  were  harvested  and  resuspended  in  Western  lysis
buffer  (50 mM NaCl, 10 mM Tris [pH 7.5],  10% glycerol,  1
mM dithiothreitol  [DTT], 0.5% NP-40), subjected  to three cy-
cles  of  freezing  and  thawing,  and  clarified  by centrifugation.
Proteins were normalized by the Bio-Rad (Hercules, CA) pro-
tein assay, and 50 m g was fractionated  by sodium dodecyl sul-
fate-polyacrylam ide gel electrophoresis (SDS-PAGE) on a 15%
polyacrylamide  gel.  Proteins  were  transferred  to  PVDF-Plus
membranes  (Micron  Separations,  Westboro,  MA)  and  incu-
bated with a mouse anti-eGFP monoclonal antibody (Clontech),
incubated  with  sheep  anti-mouse  125I-conjugated  antibodies.
(Amersham Life Science, Arlington Heights, IL) and visualized
by autoradiography.
RESULTS
The WPRE increases GFP expression in the context 
of transient transfection
To determine whether the WPRE could increase expression
of GFP cDNA from vectors delivered  by transfection,  we em-
ployed derivatives of the eGFP-C1 vector (Clontech) either con-
taining  (eGFP.stop.WPRE) or lacking (eGFP.stop) the WPRE
(Fig. 1A). GFP is detectable in intact cells by flow cytometry,
allowing  the assessment  of variations  in expression  on a per-
cell basis. In addition, GFP is already expressed well from this
plasmid in the context of transfections, the message having been
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FIG. 1. The WPRE enhances GFP expression in transiently transfected 293 cells. (A) GFP constructs used for transfection as-
says. (B and C) Flow cytometric analysis of 293 cells transiently  transfected with eGFP.stop or eGFP.stop.WPRE. x axis, GFP
fluorescence;  y axis, anti-CD4 fluorescence.  UL, UR, LL, and LR, upper left, upper right, lower left, and lower right quadrants,
respectively;  Geo Mean, geometric mean fluorescence.optimized for codon usage  and translation  and the CMV pro-
moter inducing  high levels of expression.  This made it an ap-
propriate  choice as a rigorous  test of the ability of the WPRE
to  increase  further  the  expression  of  an  efficiently  expressed
transgene.
The  ability  of  the  WPRE  to  stimulate  GFP  expression 
in  transient  transfections  was  analyzed.  eGFP.stop  or
eGFP.stop.WPRE was transfected into 293 cells by the calcium
phosphate  method. To control  for efficiency  of transfection,  a
CD4 expression plasmid was cotransfected  in each case. At 48
hr the cells were harvested,  stained  for cell surface  CD4, and
subjected  to  flow  cytometric  analysis  for  CD4  and  GFP ex-
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FIG.  2. The  WHV  PRE  enhances
transgene  expression  in 293 cells stably
transfected  with  GFP-expressing  con-
structs.  (A) 293  cells  were  transfected
with  eGFP.stop  or  eGFP.stop.WPRE,
and analyzed for GFP expression by flow
cytometry. Geometric mean fluorescence
(Geo Mean) is shown in the top left-hand
corner. (B) Southern analysis of 20 m g of
genomic  DNA  from  293  cells  stably
transfected  with  plasmid  eGFP.stop  or
eGFP.stop.WPRE.  Blotting  was  done
with GFP probe (top) or GAPDH probe
(bottom). Positions of molecular weight
standards  are indicated.  (C) The WPRE
increases the level of transgene  RNA in
both  the  nuclear  and  cytoplasmic  com-
partments of stably transfected 293 cells.
Shown is a Northern analysis of nuclear
and cytoplasmic RNA fractions prepared
from  293  cells  stably  transfected  with
plasmid eGFP.stop oreGFP.stop.WPRE.
Positions  of  the  18  and  28S  ribosomal
RNA species are indicated.pression.  The results indicated  that, on a per-cell  basis, levels
of GFP expression  increased  significantly  relative  to those  of
CD4 expression when the WPRE was included in the GFP mes-
sage (Fig. 1C). The controls  showed  less than  1% of the cell
population  in the upper right (UR) quadrant  in all cases (Fig.
1B). Plotting of GFP fluorescence on the x axis indicates a 50%
increase in the geometric mean fluorescence (X Geo Mean, Fig.
1C) of the cell population in the UR quadrant, from 78 to 121,
when eGFP.stop.WPRE is used. No such increase  is apparent
on the y axis, which represents the level of cotransfected  CD4.
Indeed, a slight decrease in CD4 was observed. It is also of note
that the inclusion of the WPRE results in a 14% increase in the
number of cells gated in the UR quadrant. The increase in GFP
fluorescence in the presence of the WPRE-containing construct
was therefore the result not of increased DNA uptake per cell,
but of increased  GFP expression  per transfected  plasmid. The
results  are  representative  of  multiple  experiments  conducted
with titrated  amounts and multiple preparations  of these plas-
mids.
The WPRE increases GFP expression in the context 
of stably transfected cell lines
The ability of the WPRE to stimulate  GFP expression  was
analyzed when stable expression  was selected with G418. The
eGFP  constructs  contain  the  neomycin/kanamycin  resistance
gene driven by the simian virus 40 (SV40) promoter. 293 cells
were transfected with eGFP.stop or eGFP.stop.WPRE, and se-
lected for stable expression with G418 (GIBCO). The cell pop-
ulations were then harvested and analyzed by flow cytometry.
The geometric  mean level of GFP expression  in the G418-re-
sistant cytometry. The geometric mean level of GFP expression
in the G418-resistant  populations  was increased  roughly nine-
fold as assessed by flow cytometry, from 29 to 249, when the
WPRE was included (Fig. 2A).
Additional  cells  from  the  stably  selected  populations  were
harvested  and subjected  to Southern analysis,  which indicated
a fourfold  greater  content  of GFP-encoding DNA in the case
of eGFP.stop than  of eGFP.stop.WPRE (Fig. 2B, top).  Equal
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FIG. 3. The WHV PRE enhances  transgene  expression  in 293 cells transiently  transduced  with recombinant  AAV. (A) Con-
structs used in AAV viral stock preparation. (B) 293 cells transiently transduced with rAAV.eGFP.W(as) or rAAV.eGFP.W were
analyzed  for GFP expression  by flow cytometry.  Geometric  mean fluorescence  is shown in the top left-hand  corner.  (C) The
WPRE increases  the level of GFP RNA in transiently transduced  293 cells. Shown is a Northern analysis of 10 m g of total cel-
lular RNA from stably selected 293 cells transduced  with rAAV.eGFP.W(as) or rAAV.eGFP.W. Position of the 18S ribosomal
RNA species  is indicated.  (D) Western  analysis  for GFP in 50 m g of protein  extracted  from 293 cells stably  transduced  with
rAAV.eGFP.W(as) or rAAV.GFP.W.loading of genomic DNA was demonstrated by hybridizing with
a glyceraldehyde-3-p hosphate dehydrogenase  (GAPDH) probe
(bottom). The decrease in copy number observed in the case of
the  WPRE-containing  construct  may  be  due  to  GFP toxicity
(Tsien, 1998). This decreased amount of GFP-WPRE encoding
DNA after stable selection  was observed  in multiple indepen-
dently  derived  cell  populations.  This  inequality  in  GFP copy
number,  while  not  allowing  direct  normalization  of  GFP ex-
pression, reveals that the effect of the WPRE on expression  is
likely greater than is apparent in the flow cytometric analysis.
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FIG. 4. The WHV PRE enhances transgene ex-
pression  in 293 cells  stably  transduced  with re-
combinant AAV. (A) 293 cells stably transduced
with rAAV.eGFP.W(as) or rAAV.eGFP.W were
analyzed for GFP expression by flow cytometry.
Geometric  mean  fluorescence  is  shown  in  the 
top  left-hand  corner.  (B) Southern  analysis  of 
genomic DNA from 293 cells stably transduced
with rAAV.eGFP.W(as) or rAAV.eGFP.W. (C)
The WPRE increases the level of transgene RNA
in stable rAAV integrants.  Shown is a Northern
analysis  of  total  cellular  RNA  from  stably 
selected  293  cells  transduced  with  rAAV.
eGFP.W(as) or rAAV.eGFP.W.To  characterize  further  the  ability  of  the  WPRE to  enhance
transgene  expression  in this context, RNA from the stably se-
lected cells was subjected to Northern analysis. Inclusion of the
WPRE caused  a roughly  fourfold  increase  in  levels  of  GFP-
containing  RNA in both the nuclear and cytoplasmic  compart-
ments of the cell (Fig. 2C, top). Probing with GAPDH demon-
strated equal loading  of RNA (bottom). These results indicate
that, per vector  copy, the WPRE-containing  construct  yielded
significantly  greater GFP RNA expression  than its counterpart
in both the nuclear and cytoplasmic  compartments.
The WPRE enhances the expression of GFP from
genes delivered by adeno-associated viral transduction
We next determined the potential of the WPRE as a tool for
increasing transgene expression in the context of AAV vectors.
The GFP and neo expression  cassettes  were inserted  between
AAV inverted terminal repeats (ITRs) in the plasmid psub201,
resulting  in  the  constructs  shown  in  Fig.  3A.  Since  AAV
genome  packaging  efficiency  is dependent  on  the  size  of the
insert  bracketed  by the ITRs (Dong et al., 1996),  the  WPRE
was inserted in the antisense orientation upstream of the CMV
promoter in construct  rAAV.eGFP.W(as) both as a control for
the presence of the WPRE and to promote equivalent  packag-
ing of the genomes in the two viruses. This configuration  was
used to avoid the inhibitory effect we had previously observed
when the WPRE was cloned in the antisense orientation within
the GFP transcript. This inhibition  is believed to be caused by
antisense  transcripts  derived  from  the  WHV  protein  X  pro-
moter, which is within the WPRE. To avoid any influence  of
the X promoter on GFP expression,  the WPRE was cloned  in
the  antisense  orientation  so  that  any  transcripts  derived  from
this promoter  could not encode  the reporter  gene.  From these
constructs,  purified  viral  stocks  were  generated  and  titrated.
Titration  determined  that a multiplicity  of infection  (MOI) of
5000 viral genomes per target cell was sufficient  to transduce
more than 90% of the target cells under the experimental con-
ditions (data not shown).
293  cells  were  transduced  with  rAAV.eGFP.W(as)  and
rAAV.eGFP.W, using an MOI of 5000 viral genomes per cell.
After 48 hr the cells were harvested, and subjected to flow cy-
tometric analysis for GFP expression. Results representative  of
multiple experiments  with multiple viral preparations  indicate
a sixfold increase in the geometric mean level of expression of
GFP, from 13 to 81, when the WPRE is included  in the GFP
message (Fig. 3B). Southern blotting of low molecular weight
DNA extracted from transduced cells indicated similar viral up-
take for both viruses (data not shown). To characterize  this ef-
fect at the RNA level and to corroborate the quantitation of GFP
by  flow  cytometry,  the transiently  transduced  cells  were  har-
vested and subjected to Northern and Western analysis. North-
ern analysis of total cellular RNA, shown in Fig. 3C, indicated
a threefold increase in GFP RNA. Amounts of GFP RNA were
normalized relative to histone 2B message detected by coprob-
ing  with an  H2B fragment.  This  result  demonstrates  that  the
WPRE must be located  within the GFP message to stimulate
gene  expression,  suggesting  that  the  WPRE functions  at  the
posttranscriptiona l level  in the  AAV vector  context.  Western
analysis  of transduced  cell lysates  (Fig. 3D) showed a seven-
fold  increase  in  GFP  protein  in  the  presence  of  the  WPRE,
which corresponds  well with the sixfold increase in GFP fluo-
rescence  as  assessed  by  flow  cytometry.  The  Northern  and
Western  analyses  exhibit  different  fold  increases  when  the
WPRE is included  in the viral construct.  This difference  may
be due to a translational  effect of the WPRE.
To assay the effect of the WPRE on the expression  of GFP
in stably transduced cells, 293 cells were transduced with 5000
genomes  per  target  cell  of  viruses  rAAV.eGFP.W(as)  and
rAAV.eGFP.W, and placed under selection with G418. The sta-
bly transduced  cells were subjected to flow cytometric, South-
ern, and Northern analyses. Figure 4A shows the results of flow
cytometric  analysis  for  GFP  fluorescence.  The  effect  of  the
WPRE,  a  roughly  eightfold  increase  in  geometric  mean  ex-
pression of GFP from 24 to 183, was similar to that observed
in stably transfected cells. Southern analysis with a GFP probe
indicated  that the copy number of integrated,  GFP-expressing
AAV genomes  in  the  different  cell  populations  was  roughly
equivalent (Fig. 4B). No evidence of GFP toxicity was observed
under these conditions. This is likely due to the low copy num-
ber present as a result of AAV transduction, on the order of one
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FIG. 5. The WPRE enhances GFP expression in primary hu-
man fibroblasts. (A) Primary human skin fibroblasts  were sta-
bly transduced with rAAV.eGFP.W(as) or rAAV.eGFP.W and
analyzed  for  GFP  expression  by  flow  cytometry.  Geometric
mean  fluorescence  is shown  in  the  top  left-hand  corner.  (B)
Southern analysis of 10 m g of genomic DNA from primary hu-
man skin fibroblasts stably transduced with rAAV.eGFP.W(as)
or rAAV.eGFP.W. Blot was probed for GFP. GAPDH probing
revealed equal loading of DNA (data not shown).to four, compared with the stably transfected cells, which could
contain 10 or more copies of the GFP gene.
Northern  analysis  was  performed  on  total  cellular  RNA 
isolated  from the stably transduced  populations.  Probing with
GFP and histone  2B as a loading  control  indicated  a fourfold
increase  in  the  amount  of  GFP message  present  in  the  cells
transduced  with  rAAV.eGFP.W  relative  to  those  transduced
with  rAAV.eGFP.W(as)  (Fig.  4C).  Probing  of  this  blot  for
neomycin/kanamycin  RNA  revealed  that  the  increase  in  ex-
pression of GFP yielded  by the WPRE is not related to an el-
evation of neomycin expression.
The WPRE enhances GFP expression in primary
human fibroblasts transduced with recombinant AAV
The utility of the WPRE in a gene therapeutic  context  will
be dependent  on its ability  to function  in nontransformed hu-
man cells. To assess the plausibility of using the WPRE to en-
hance gene expression in such settings, 5000 genomes per tar-
get cell of viruses rAAV.eGFP.W(as) and rAAV.eGFP.W were
used to transduce cultured primary human fibroblasts. The pri-
mary cells were acquired at a low passage number (passage 7)
so as to allow ample time for selection  and analysis. After 48
hr the cells were placed in selective medium (200 m g of G418
per milliliter).  After 3 weeks of selection,  the remaining cells
were harvested  and  subjected  to flow cytometric  analysis  for
GFP expression.  The results indicate  a sixfold  increase  in the
geometric mean level of expression of GFP when the WPRE is
included  in the GFP message (Fig. 5A). Southern analysis  of
genomic DNA, using a probe for GFP sequence, indicated that
there is a slightly greater content of GFP-encoding DNA in the
case  of rAAV.eGFP.W(as) than  of rAAV.eGFP.W (Fig. 5B).
Reprobing for GAPDH revealed equal loading of genomic DNA
(data not shown). These results are similar to those observed in
293 cells, and indicate that the WPRE can function to enhance
gene expression in a heterologous  viral context in cultured pri-
mary human cells.
DISCUSSION
Techniques  currently  used to introduce  transgenes  into tar-
get cells for gene therapy are based largely on methods evolved
by viruses to deliver their genomes into host cells. The devel-
opment of a new gene therapeutic vector frequently begins with
a set of decisions regarding the best way to alter an existing vi-
ral genome; the virus must be made to contain the transgene of
interest,  incorporate  it  chromosomally  or  episomally  into  the
desired  cells,  and  allow  it to  be  transcribed  to  a satisfactory
level. While much effort has been spent optimizing gene ther-
apeutic vectors for high titer, efficiency of entry, and sufficient
levels of transcription,  less progress has been made in the ap-
plication of posttranscriptiona l methods for improving gene ex-
pression. New insight is rapidly being acquired into how viruses
ensure high levels of expression of their genes at the posttran-
scriptional  level. Multiple viruses have been shown to possess
cis- and trans-acting elements whose purpose is to increase the
expression  of viral genes by interacting with host cell machin-
ery (Malim et al., 1989; Fischer et al., 1994; Huang and Yen,
1994;  Donello  et  al., 1996,  1998;  Pasquinelli  et  al., 1997;
Saavedra et al., 1997). Previous work with the PREs has demon-
strated  their  ability  to  rescue  the  expression  of  unspliced  re-
porter messages (Donello et al., 1998), and of messages whose
expression is dependent on the presence of introns (Huang and
Yen,  1995)  or  posttranscriptiona l  elements  (Donello  et  al.,
1998). This study and our previous work demonstrate  that the
WPRE can further increase the expression of a gene that is al-
ready  well expressed.  This suggests  that enhancement  can be
expected to occur for a variety of potentially therapeutic genes,
and will not be limited to genes that are difficult to express, al-
though the benefit may be more dramatic in these cases.
We find that the WPRE is capable of enhancing the expres-
sion of GFP in the contexts of transient and stable transfection
as well as in the context  of DNA delivery  by vectors  derived
from AAV. Only when the WPRE was located  within a mes-
sage did it have the ability to stimulate gene expression, demon-
strating that the WPRE functions at the posttranscriptiona l level.
It is possible that the WPRE contains an orientation-depend ent
transcriptional  enhancer  that functions  in AAV. However, we
believe  that this is unlikely  since  the WPRE region  has been
shown by several  laboratories  to have  no detectable  enhancer
activity  in a variety  of contexts.  Analysis  of RNA in the nu-
clear and cytoplasmic  compartments  of stably transfected  293
cell populations revealed that the WPRE increased the amounts
of message in both compartments. The nucleocytoplasm ic ra-
tio relative to messages lacking the WPRE was not altered. In
all cases, the increase  in GFP protein  expression  mediated  by
the WPRE was approximately twofold greater than the observed
increase in RNA, suggesting  that the WPRE may also slightly
stimulate  the efficiency  of translation.  Together,  these  results
suggest  that the WPRE may have positive  effects on gene ex-
pression in both the nuclear and cytoplasmic  compartments of
the cell. In addition, the WPRE is capable of enhancing the ex-
pression  of GFP in primary  human cells,  establishing  that its
mechanism of enhancement is not dependent on the transformed
state of the cells. Inclusion of the WPRE is thus a viable means
of increasing  transgene  expression  in normal human tissue.
These  results,  together  with  our  previous  finding  that  the
WPRE  can  stimulate  transgene  expression  in  the  context  of
retroviral and lentiviral vectors, indicate that the WPRE will be
a broadly  useful tool for increasing  levels  of gene  expression
in multiple  gene  therapeutic  and research  settings.  The effect
of the WPRE on gene expression has been demonstrated in both
RNA and DNA viruses,  as well as in transfections  with plas-
mid  DNA. Thus,  the  increase  in  expression  mediated  by  the
WPRE is not attributable  to the enhancement  of an event in a
specific viral life cycle. The WPRE can therefore be used in all
gene delivery  systems  presently  in clinical  trial, as well as in
vectors  currently  being  designed  and  preclinically  evaluated.
The ability of the WPRE to increase the expression of each de-
livered DNA template will allow higher levels of transgene ex-
pression  to be achieved  per transduction  event  with currently
available  delivery  systems.  Such an increase  in efficacy  may
permit the monetary cost of a course of gene therapy to be sig-
nificantly reduced. Inclusion of the WPRE at the stage of vec-
tor design will permit a given therapeutic  goal to be achieved
with substantially less virus, thereby decreasing the cost of pro-
ducing the reagents for therapy. The optimization of presently
existing  vectors  may, as much  as  the  design  of  new vectors,
contribute to the arrival of gene therapy as clinical reality. The
WHV PRE ENHANCES GENE EXPRESSION IN AAV 2303woodchuck hepatitis viral PRE will be a useful addition to next-
generation  gene  delivery  systems,  which  will incorporate  mea-
sures to optimize gene expression at the posttranscriptional  level.
ACKNOWLEDGMENTS
The authors gratefully  acknowledge  Allison Bocksruker for
assistance  in preparing  this manuscript,  John Donello and Dr.
Romain Zufferey for helpful discussion,  Lara Yurchak for the
gift of the pCMXCD4 vector, and Dr. Wei Jiang for the gift of
the primary fibroblasts.  J.E.L. is a Chapman Scholar. M.D.W.
is supported  by the Oracle Foundation,  by a gift from Odette
Wurzburger,  and by a grant  from the President’s Club of the
Salk Institute.  T.J.H. is supported  by the Gene and Ruth Pos-
ner Foundation. This work was supported by Arthur and Larry
Kramer. This work is dedicated  to  the  memory of Jeffrey  A.
Posner.
REFERENCES
ANTONIOU, M., GERAGHTY, F., HURST, J., and GROSVELD, F.
(1998). Efficient 39 -end formation of human beta-globin  mRNA in
vivo  requires  sequences  within  the  last  intron  but  occurs  indepen-
dently of the splicing reaction. Nucleic Acids Res. 26, 721–729.
BUCHMAN, A.R.,  and  BERG,  P. (1988).  Comparison  of  intron-de-
pendent and intron-independe nt gene expression. Mol. Cell. Biol. 8,
4395–4405.
CARTER,  B.J.  (1992).  Adeno-associated  virus  vectors.  Curr.  Opin.
Biotechnol.  3, 533–539.
CHEUNG,  A.K.,  HOGGAN,  M.D.,  HAUSWIRTH,  W.W.,  and
BERNS,  K.I.  (1980).  Integration  of  the  adeno-associated  virus
genome into cellular DNA in latently infected human Detroit 6 cells.
J. Virol. 33, 739–748.
CHOI, T., HUANG, M., GORMAN, C., and JAENISCH, R. (1991). A
generic  intron  increases  gene  expression  in  transgenic  mice.  Mol.
Cell. Biol. 11, 3070–3074.
DONELLO, J.E., BEECHE, A.A., SMITH, G.R., LUCERO, G.R., and
HOPE, T.J., (1996). The hepatitis  B virus posttranscriptional regu-
latory  element  is  composed  of  two  subelements.  J.  Virol.  70,
4345–4351.
DONELLO, J.E., LOEB, J.E., and HOPE, T.J. (1998). Woodchuck he-
patitis  virus  contains  a tripartite  posttranscriptional  regulatory  ele-
ment. J. Virol. 72, 5085–5092.
DONG, J.Y., FAN, P.D., and  FRIZZELL,  R.A. (1996).  Quantitative
analysis of the packaging  capacity of recombinant adeno-associated
virus. Hum. Gene Ther. 7, 2101–2112.
FISCHER,  U.,  MEYER,  S.,  TEUFEL,  M.,  HECKEL,  C.,
LUHRMANN, R., and RAUTMANN, G. (1994). Evidence that HIV-
1 Rev directly promotes the nuclear export of unspliced RNA. EMBO
J. 13, 4105–4112.
FISHER,  K.J.,  GAO,  G.P.,  WEITZMAN,  M.D.,  DEMATTEO,  R.,
BURDA,  J.F.,  and  WILSON,  J.M.  (1996).  Transduction  with  re-
combinant adeno-associated virus for gene therapy is limited by lead-
ing-strand synthesis. J. Virol. 70, 520–532.
FLOTTE, T.R., and CARTER, B.J. (1995). Adeno-associated virus vec-
tors for gene therapy. Gene Ther. 2, 357–362.
FLOTTE,  T.R.,  AFIONE,  S.A.,  CONRAD,  C.,  MCGRATH,  S.A.,
SOLOW,  R.,  OKA,  H.,  ZEITLIN,  P.L.,  GUGGINO,  W.B.,  and
CARTER, B.J. (1993). Stable in vivo expression of the cystic fibro-
sis transmembrane conductance  regulator  with an adeno-associated
virus vector. Proc. Natl. Acad. Sci. U.S.A. 90, 10613–10617.
HARRIS,  M.E.,  DONELLO,  J.E.,  LOEB,  J.E.,  OTERO,  G.C.,  and
HOPE, T.J.  (1999).  A  cis-acting  RNA element  that  increases  ex-
pression by promoting longer polyadenylated  tails. (In preparation.)
HUANG, Y., WIMLER, K.M., and CARMICHAEL, G.G. (1999). In-
tronless mRNA transport elements may affect multiple steps of pre-
mRNA processing. EMBO J. 18, 1642–1652.
HUANG, Z.M., and YEN, T.S. (1994). Hepatitis B virus RNA element
that facilitates accumulation  of surface gene transcripts in the cyto-
plasm. J. Virol. 68, 3193–3199.
HUANG, Z.M., and  YEN, T.S. (1995). Role of the  hepatitis  B virus
posttranscriptional  regulatory  element  in  export  of  intronless  tran-
scripts. Mol. Cell. Biol. 15, 3864–3869.
KOTIN, R.M. (1994). Prospects for the use of adeno-associated virus
as a vector for human gene therapy.  Hum. Gene Ther. 5, 793–801.
LAUGHLIN, C.A., CARDELLICHIO, C.B., and COON, H.C. (1986).
Latent  infection  of KB cells with adeno-associated virus type 2. J.
Virol. 60, 515–524.
MALIM, M.H., HAUBER, J., LE, S.Y., MAIZEL, J.V., and CULLEN,
B.R. (1989). The HIV-1 Rev trans-activator acts through a structured
target sequence to activate nuclear export of unspliced viral mRNA.
Nature (London) 338, 254–257.
MCLAUGHLIN, S.K., COLLIS, P., HERMONAT, P.L., and MUZY-
CZKA, N. (1988). Adeno-associated virus general transduction vec-
tors: Analysis of proviral structures. J. Virol. 62, 1963–1973.
MURPHY,  J.E.,  ZHOU,  S.,  GIESE,  K.,  WILLIAMS,  L.T.,  ES-
COBEDO, J.A. and DWARKI, V.J. (1997). Long-term correction of
obesity and diabetes in genetically obese mice by a single intramus-
cular  injection  of  recombinant  adeno-associated  virus  encoding
mouse leptin. Proc. Natl. Acad. Sci. U.S.A. 94, 13921–13926.
NESIC, D., CHENG, J., and MAQUAT, L.E. (1993). Sequences within
the last intron  function  in RNA 39 -end formation in cultured  cells.
Mol. Cell. Biol. 13, 3359–3369.
PASQUINELLI, A.E., ERNST, R.K., LUND, E., GRIMM, C., ZAPP,
M.L., REKOSH, D., HAMMARSKJOLD, M.L., and DAHLBERG,
J.E.  (1997).  The  constitutive  transport  element  (CTE)  of
Mason–Pfizer monkey virus (MPMV) accesses a cellular mRNA ex-
port pathway. EMBO J. 16, 7500–7510.
RYU, W.S., and MERTZ, J.E. (1989). Simian virus 40 late transcripts
lacking excisable intervening sequences are defective in both stabil-
ity  in  the  nucleus  and  transport  to  the  cytoplasm.  J.  Virol.  63,
4386–4394.
SAAVEDRA, C., FELBER, B., and IZAURRALDE, E. (1997).  The
simian retrovirus-1 constitutive  transport element, unlike the HIV-1
RRE, uses factors required for cellular mRNA export. Curr. Biol. 7,
619–628.
SAMULSKI, R.J., CHANG, L.S., and SHENK, T. (1987). A recom-
binant  plasmid  from  which  an  infectious  adeno-associated  virus
genome can be excised in vitro and its use to study viral replication.
J. Virol. 61, 3096–3101.
SAMULSKI, R.J., CHANG, L.S., and SHENK, T. (1989). Helper-free
stocks of recombinant  adeno-associated viruses: Normal integration
does not require viral gene expression. J. Virol. 63, 3822–3828.
SMITH,  G.J.,  III,  DONELLO,  J.E.,  LÜCK,  R.,  STEGER,  G.,  and
HOPE, T.J. (1998). The hepatitis  B virus post-transcriptional  regu-
latory element contains  two conserved  RNA stem-loops  which are
required for function.  Nucleic Acids Res. 26, 4818–4827.
SNYDER, R.O., MIAO, C.H., PATIJN, G.A., SPRATT, S.K., DANOS,
O.,  NAGY, D., GOWN, A.M.,  WINTHER, B.,  MEUSE,  L.,  CO-
HEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997). Persistent
and therapeutic concentrations  of human factor IX in mice after he-
patic gene transfer of recombinant AAV vectors. Nature Genet. 16,
270–276.
TSIEN, R. (1998). The green fluorescent protein. Annu. Rev. Biochem.
67, 509–544.
WANG, J.M.,  ZHENG, H.,  SUGAHARA, Y.,  TAN, J.,  YAO, S.N.,
LOEB ET AL. 2304OLSON, E., and KURACHI, K. (1996). Construction of human fac-
tor IX expression  vectors in retroviral vector frames optimized  for
muscle cells. Hum. Gene Ther. 7, 1743–1756.
XIAO, X.,  LI,  J.,  and  SAMULSKI, R.J.  (1996).  Efficient  long-term
gene transfer into muscle tissue of immunocompetent mice by adeno-
associated virus vector. J. Virol. 70, 8098–8108.
XIAO, X., LI, J., MCCOWN, T.J., and SAMULSKI, R.J. (1997). Gene
transfer by  adeno-associated virus  vectors  into  the  central nervous
system. Exp. Neurol. 144, 113–24.
XIAO, X., LI. J., and  SAMULSKI, R.J. (1998).  Production  of high-
titer  recombinant  adeno-associated virus  vectors  in  the  absence  of
helper adenovirus. J. Virol. 72, 2224–2232.
ZUFFEREY,  R.,  DONELLO,  J.E.,  TRONO,  D.,  and  HOPE,  T.J.
(1999). Woodchuck hepatitis virus post-transcriptional regulatory el-
ement (WPRE) enhances expression of transgenes delivered by retro-
viral vectors. J. Virol. 73, 2886–2892.
Address reprint  requests  to:
Dr. Thomas J. Hope
The Salk Institute  for Biological  Studies
10010 N. Torrey Pines Road
Infectious  Disease Laboratory
P.O. Box 85800
La Jolla, CA 92037
E-mail: Hope@salk.edu
Received for publication  March 15, 1999; accepted after revi-
sion June 29, 1999.
WHV PRE ENHANCES GENE EXPRESSION IN AAV 2305